ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation

A disintegrin and metalloproteinase-17 (ADAM17) can cut and release a wide variety of epidermal growth factor receptor (EGFR) ligands to promote survival, invasion and proliferation of cancer cell, and therefore, is considered to be a potential therapeutic target for cancer. The main goal of the pre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of oncology 2016-08, Vol.49 (2), p.682-690
Hauptverfasser:	Meng, Xiangchao, Hu, Baoshan, Hossain, Mohammad Monir, Chen, Guofu, Sun, Ying, Zhang, Xuepeng
Format:	Artikel
Sprache:	eng
Schlagworte:	a disintegrin and metalloprotease 17 ADAM17 Protein - antagonists & inhibitors ADAM17 Protein - genetics Animals Benzamides - administration & dosage Binding sites Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cell adhesion & migration Cell growth Cellular signal transduction Chromones - administration & dosage Development and progression Diphenylamine - administration & dosage Diphenylamine - analogs & derivatives EGFR-PI3K-AKT signaling pathway Enzymes Female Gene amplification Gene expression Genetic aspects Growth factors Health aspects Humans Kinases MCF-7 Cells Medical prognosis Metastasis Mice Morpholines - administration & dosage Phosphatidylinositol 3-Kinase - antagonists & inhibitors Phosphatidylinositol 3-Kinase - genetics Proteases Proteins Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins c-akt - genetics Quinazolines - administration & dosage Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics RNA, Small Interfering - genetics Signal Transduction - drug effects small interference RNA Studies targeted therapy Tumor necrosis factor-TNF Tumors Tyrphostins - administration & dosage Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!